Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The influenza virus endonuclease domain is an essential subdomain of the viral RNA-dependent RNA polymerase complex. It is located within the N-terminal domain of the PA subunit and is responsible for cleaving host pre-mRNAs to generate primers required for viral mRNA synthesis, a process known as "cap-snatching." This activity is crucial for the transcription and replication of the viral genome and makes the endonuclease domain a highly attractive target for antiviral drug development. The active site contains conserved residues that coordinate two divalent metal ions (typically manganese or magnesium), which are essential for catalytic activity. Small molecule inhibitors, such as L-742,001 and baloxavir marboxil, can bind directly to this endonuclease active site. Resistance mutations map directly within this region.
Inhibition of endonuclease activity, preventing viral mRNA synthesis
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza Virus Endonuclease Domain (PA-Nter).